New hope for tough blood cancers: first human trial of GEN3018 begins

NCT ID NCT07384715

Recruiting now Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Feb 03, 2026 · Last updated Apr 30, 2026 · Updated 17 times

Summary

This early-stage trial tests a new antibody drug, GEN3018, in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the best dose. Up to 78 participants will receive the drug, and the study lasts about one year with regular check-ups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aarhus Universitetshospital - Skejby
RECRUITING

Aarhus, Denmark, 8200, Denmark
Charite Campus Virchow-Klinikum
NOT_YET_RECRUITING

Berlin, State of Berlin, Germany
Copenhagen Rigshospitalet
RECRUITING

Copenhagen, Denmark, 2100, Denmark
Klinikum der Universität München Großhadern
NOT_YET_RECRUITING

Munich, Munich, Germany
Universitätsklinikum Carl Gustav Carus Dresden
NOT_YET_RECRUITING

Dresden, Dresden, Germany

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA HIGHER-RISK MYELODYSPLASTIC SYNDROME HIGHER-RISK MYELODYSPLASTIC SYNDROME R/R AML R/R AML R/R HR-MDS R/R HR-MDS